Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: Theory and application to HIV treatment

Mathematical Biosciences

Volumn 176, Issue 2, 2002, Pages 185-202

  Hlavacek, William S ^a   Percus, Jerome K ^b   Percus, Ora E ^b   Perelson, Alan S ^a   Wofsy, Carla ^c  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

B lymphocyte; Birth death Markov chain; Follicular dendritic cell; Human immunodeficiency virus type 1; Immune memory; Multivalent ligand receptor binding

Indexed keywords

DENDRIMERS; DIFFUSION; PATIENT TREATMENT; TISSUE; VIRUSES;

RETENTION;

ANTIGENS;

ANTIRETROVIRUS AGENT;

HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; B LYMPHOCYTE; COMPLEMENT SYSTEM; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; LONG TERM CARE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PERSISTENT VIRUS INFECTION; RECEPTOR BINDING; THEORY; VIRION; VIRUS CELL INTERACTION; VIRUS EXPRESSION;

ANTI-HIV AGENTS; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; DENDRITIC CELLS, FOLLICULAR; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, IMMUNOLOGICAL; RECEPTORS, COMPLEMENT 3D;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036231339     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-5564(02)00091-3     Document Type: Article

References (60)

1. Follicular dendritic cells as accessory cells
2. The follicular dendritic cell: Long term antigen retention during immunity
3. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection
4. + T cell demographics and dynamics in lymphatic tissues
5. Quantitative image analysis of HIV-1 infection in lymphoid tissue
6. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection
7. Follicular dendritic cells and human immunodeficiency virus infectivity
8. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent
9. Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia
10. Influence of follicular dendritic cells on HIV dynamics
11. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy
12. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood
13. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
14. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
15. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy
16. Lymph node architecture preceding and following 6 months of potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen. Restoration after involution and CD4 cell depletion in an AIDS patient
17. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy
18. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
19. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
20. HIV-1 replication in patients with undetectable plasma virus receiving HAART
21. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy
22. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
23. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
24. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
25. Follicular dendritic cells (FDC) in retroviral infection: Host/pathogen perspectives
26. Persistence of infectious HIV on follicular dendritic cells
27. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
28. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
29. Latent reservoirs of HIV: Obstacles to the eradication of virus
30. Decay characteristics of HIV-1-infected compartments during combination therapy
31. + T cell homeostasis and function in advanced HIV disease
32. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection
33. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection
34. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: Implications for timing of antiretroviral therapy
35. Impact of TNFα, LTα, FcγRII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients
36. Dissociation of HIV-1 from follicular dendritic cells during HAART: Mathematical analysis
37. Role of complement in HIV infection
38. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2
39. c receptors
40. Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction
41. Membrane complement receptors specific for bound fragments of C3
42. Determination of the size of HIV using adenovirus type 2 as an internal length marker
43. Structural biology of HIV
44. Molecular modelling study of HIV p17gag (MA) protein shell utilising data from electron microscopy and X-ray crystallography
45. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1
46. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes
47. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: Role of complement
48. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
49. Receptor clustering on a cell surface. III. Theory of receptor cross-linking by multivalent ligands: Description by ligand states
50. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23
51. Quantification of C3dg/Epstein-Barr virus receptors on human B cells and B cell lines
52. Decreased expression of complement receptory type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia
53. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens
54. Isolated follicular dendritic cells: Cytochemical antigen localization, Nomarski, SEM, and TEM morphology
55. Competition between solution and cell surface receptors for ligand: Dissociation of hapten bound to surface antibody in the presence of solution antibody
56. Diffusion limited effects of receptor clustering
57. Why is it so hard to dissociate multivalent antigens from cell-surface antibodies?
58. Kinetics of multivalent antigen DNP-BSA binding to IgE-FcεRI in relationship to the stimulated tyrosine phophorylation of FcεRI
59. Quantifying aggregation of IgE-FcεRI by multivalent antigen